Anglonordic Life Science Conference showcases best in Europe’s life science scene
The great and good of Europe’s biotech scene descended on London on Wednesday and Thursday, with over 370 delegates from leading and upcoming drug discovery and technology companies in the UK, Nordic and other European regions attending the main event in County Hall.
With over 90 investment firms participating and 36 funding pitches, this 20th edition of the conference was one of the top networking and partnering events of 2024.
The event was made possible with the help of lead and founding sponsor M Ventures.
Attendees were treated to an insightful keynote address by Shaun Grady, Vice President for Business Development Operations at AstraZeneca, who outlined how CEO Pascal Soriot has transformed the business since his appointment in 2012.
Other panels included:
Lisa Urquhart chairing thought leaders from Alchemab Therapeutics Ltd, Asceneuron SA, Mission Therapeutics & Vesper Bio, who discussed novel approaches and targets to tackle #neurodegeneration.
Top investors Hakan Goker, Allan Marchington, Erica Whittaker & Roel Bulthuis joined host Stephen Hansen, to share trends in Life Science Investment.
Megan Thomas spoke with Jérémie Laurent of Astraveus, Christian Uhrich of M Ventures, Miquel Vila-Perello of SpliceBio and Arnaud Autret of Illumina Ventures and discussed ‘What’s next for Cell & Gene Therapies’.
Mike Ward uncovered key learnings from the careers of top industry executives – Simon Kerry of Curve Therapeutics, Christoph Vahl of Merck Healthcare, Khatereh Ahmadi of MSD and Tim Edwards of STORM Therapeutics Limited
Roald Dahl’s Marvellous Children’s Charity was the event’s Charity of the Year 2024 and provides over 120 specialist nurses to support seriously ill children.
4SC AG: Paediatric Investigation Plan waiver for resminostat from the UK MHRA received
4SC AG, a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma CTCL, on Monday announced that it has received a Paediatric Investigation Plan (PIP) product-specific waiver from UK Medicines & Healthcare products Regulatory Agency (MHRA) for resminostat (Kinselby), an oral maintenance treatment for advanced stage CTCL.
The move supports resminostat’s Marketing Authorisation Application in the UK by removing the requirement to conduct paediatric clinical studies, when the medicine is not needed or is inappropriate for children. Based in Planegg-Martinsried, Germany, 4SC followed this on Thursday with publication of its Q1 2024 report, which is available from its website.
Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium
Eindhoven, Netherlands-based Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, on Wednesday announced two presentations on its ground-breaking treatment options during the 46th Annual Charing Cross Symposium, the symposium in the field of vascular and endovascular education being held in London from 23rd-25th April 2024.
Two key presentations by leading KOLs highlight positive results from trials of aXess, a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, long-term living vessel, in adult patients with end-stage renal disease who need vascular access to hemodialysis.
Outrun Therapeutics launches with a $10m seed financing from M Ventures and MP Healthcare Venture Management to develop a protein stabilisation pipeline
Outrun Therapeutics, the E3 ligase inhibitor and protein stabilisation specialist, exited from stealth following a $10m seed financing round. Dundee, Scotland-based Outrun’s platform has enabled it to rapidly build a pipeline of highly selective, small molecule, first-in-class E3 ligase inhibitors, as well as identify novel E3 ligase targets across multiple disease areas. Outrun’s lead programme is focused on hard-to-treat solid tumours.
The technology Originates from the lab of Prof Satpal Virdee at the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee and is backed by M Ventures and MP Healthcare Venture management.
